NCT06161805RecruitingPhase 3
Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study
Source: ClinicalTrials.gov · Last updated 11 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this randomized controlled trial is to investigate the effect of esketamine versus placebo on the NRS score for chronic pelvic pain. Secondary endpoints are to assess pain scores, side-effects, quality of life, depressive symptoms and pain coping.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 23 Oct 2023
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Reinier de Graaf Groep
- Diseases
- Endometriosis
- NCT number
- NCT06161805
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 56
- From 1 Mar 2024 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Usage of strong opioid medication
- Alcohol or drug abuse
Other illness
- Poorly regulated hypertension, \>180/100mmHg at rest
- Patients with thyroid disease
- Patients with cancer
- History of psychiatric illness (schizophrenia, psychosis, delirium, manic depression)
- Serious medical disease (e.g., cardiovascular, renal , pulmonary or liver disease)
- Severe liver disease
- Unstable angina, heart failure, history of cerebral vascular accident (CVA)
- Patients suffering from an active infection
- Patients with epilepsy
- Patient with a known (es)ketamine allergy
Lab values
- Abnormal liver enzyme levels at baseline (ASAT, ALAT, GGT, AF, Bilirubin total)
- Patients are allowed to continue the following pain medications: paracetamol, non-steroidal anti-inflammatory drugs as described previously by Sigtermans et al. (Trial NL466 (NTR507))\* according to their stable use in dose and frequency.
- \*in case of tramadol, amitriptylin, selective serotonin reuptake-inhibitors, gabapentin and pregabalin, the usage may also be continued during this study.
Other
- Pain score \<6 out of 10 (NRS) for chronic pelvic pain
- Endometriosis affecting the bladder and ureter
- Increased intracranial pressure
- Patients with glaucoma
- Usage of xanthine derivatives or ergometrine
- Patients trying to achieve pregnancy and or patients who are breastfeeding
- Not being able to answer questionnaires (in Dutch)
- Mentally incompetent (patients not able to make decisions that are in their best interests, this will be evaluated by their treating physician (e.g. patients with an intellectual disability or mental retardation))
Who the study is looking for
- Women
- All pre-menopausal women aged above 18 years
- Diagnosed with endometriosis (ultrasound, MRI or previous laparoscopic and/or diagnostic surgery) according to the #Enzian classification \[52\]. This means that endometriosis is present in the following compartments:
- Rectovaginal space (minimal A1) and/or
- Sacrouterine ligaments, cardinal ligaments, pelvic sidewall (minimal B1) and/or
- Rectum (minimal C1) and/or
- Endometriosis of the intestines, diaphragm and/or
- Adenomyosis (according to the morphological uterus sonographic assessment (MUSA) or evident adenomyosis on the MRI) \[53, 54\] and/or
- Peritoneal / superficial endometriosis (diagnosed laparoscopically and not treated during surgery).
- Mild to severe chronic pelvic pain (NRS scale \>= 6). The 11-point NRS scale ranges from '0' representing no pain to '10' representing the worst pain imaginable.
- Resistant to current recommended lines of analgesics (paracetamol, NSAIDs)
- Usage of strong opioids must not have been prescribed or otherwise have been discontinued for more than 1 week.
- An indication for endometriosis resection surgery or on the waiting list for surgical treatment
- Ability to understand the patient information letter and to give oral and written informed consent
- No alteration in the utilization of hormonal therapy ≤1 months prior to inclusion.
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nederlandse Endometriose Kliniek, Reinier de Graaf Gasthuis Coordinator of this site? Confirm its status | Delft | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.